Zimbabwe has rejected a substantial US health deal valued at $367m (£272m) over five years due to Washington's request for confidential data.
This rejection was revealed after a government memo from December was leaked, which showed Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative later clarified that the United States was seeking genetic material for research and commercial purposes while refused to share the benefits from any future vaccines.
"We will now turn to the difficult and regrettable process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for continued negotiations to reach a agreement suitable to all parties so the country's critical HIV programme can be sustained.
Wider Context
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a court halted a similar health funding agreement following legal challenges were filed about the security of Kenyans' medical information.
After resuming the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump stated its spending was "wasteful" and his administration was seeking direct bilateral deals to enhance openness and accountability.
According to statements, Sixteen nations in Africa have to date agreed to similar health pacts, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration would have delivered extraordinary benefits for Zimbabwean communities, particularly the 1.2 million presently on antiretroviral therapy through US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to provide its biological resources and data indefinitely, with no equivalent guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"In essence, our country would provide the basic resources for medical research without any assurance that the resulting innovations would be accessible to our population should a new health crisis arise."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting systems already set up via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with potential global health emergencies.
"This system is designed to guarantee that when a country provides its data, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome continued dialogue with our US partners on how future co-operation might be designed in a manner that respects the independence and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but urged that talks should continue since much of the nation's HIV programmes relied on external financing.
"Where specific concerns exist, such as those relating to information security or agreement terms, these can often be resolved through technical clarification and negotiated safeguards," the group added.
The halted deal emphasises the ongoing challenges between accepting crucial foreign assistance and safeguarding national sovereignty in an ever more data-driven world.